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SUMMARY
It is well understood that fatty acids can be synthesized, imported, and modified to meet requisite 
demands in cells. However, following the movement of fatty acids through the multiplicity of 
these metabolic steps has remained difficult. To better address this problem, we developed Fatty 
Acid Source Analysis (FASA), a model that defines the contribution of synthesis, import, and 
elongation pathways to fatty acid homeostasis in saturated, monounsaturated, and polyunsaturated 
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fatty acid pools. Application of FASA demonstrated that elongation can be a major contributor to 
cellular fatty acid content and showed that distinct pro-inflammatory stimuli (e.g., Toll-like 
receptors 2, 3, or 4) specifically reprogram homeostasis of fatty acids by differential utilization of 
synthetic and elongation pathways in macrophages. In sum, this modeling approach significantly 
advances our ability to interrogate cellular fatty acid metabolism and provides insight into how 
cells dynamically reshape their lipidomes in response to metabolic or inflammatory signals.
Graphical Abstract
In Brief
Argus et al. developed Fatty Acid Source Analysis (FASA), a model that quantifies cellular fatty 
acid synthesis, elongation, and import. FASA is used to demonstrate that elongation can be a 
major contributor to cellular fatty acid content and that different stimuli reprogram macrophage 
fatty acid elongation pathways in distinct ways.
INTRODUCTION
Individual cells meet their fatty acids requirements through a combination of synthesis, 
import, and modification pathways (Vance and Vance, 2008). Long-chain fatty acids 
(LCFAs; 14 to 18 carbons) are synthesized through the enzymatic action of fatty acid 
synthase (FASN), producing primarily palmitic acid (16:0) and, to a lesser extent, 14:0 and 
18:0 through the condensation of acetyl-coenzyme A (CoA) with malonyl-CoA (Vance and 
Vance, 2008; Wakil, 1989). These direct LCFA products of FASN can be further modified 
by both elongation and desaturation. The fatty acid desaturation pathways selectively 
oxidize fatty acids, introducing desaturations into the aliphatic tails. The fatty acid 
elongation enzymes lengthen a wide variety of fatty acids by 2 carbons per cycle through 
addition of malonyl-CoA (derived from acetyl-CoA) (Vance and Vance, 2008). In addition to 
synthesis, elongation, and desaturation, fatty acids can be imported directly from the 
extracellular space. These imported fatty acids can also enter cellular elongation or 
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desaturation pathways as required (Sassa and Kihara, 2014; Vance and Vance, 2008). In 
combination, these metabolic pathways allow cells to generate a wide variety of fatty acids 
commonly ranging from 14 to 24 carbons for use as free fatty acids and for incorporation 
into complex lipids. Consequently, the development of models that are capable of unraveling 
the complex nature of fatty acid homeostasis will be important for elucidating how cells 
achieve their cellular lipid composition under normal conditions and the extent to which 
these pathways are deranged in pathologic states.
The multiplicity of metabolic pathways contributing to fatty acid pools makes identifying 
the “source” of a fatty acid nearly impossible without the use of labeling strategies. 
Isotopomer spectral analysis (ISA) and mass isotopomer distribution analysis (MIDA) are 
independent modeling approaches that infer fatty acid metabolic parameters using mass 
spectrometry data from cells or tissues cultured with stable isotope-labeled metabolites such 
as glucose or glutamine (Hellerstein and Neese, 1992; Kelleher and Masterson, 1992). In 
classical ISA and MIDA models, there is an underlying assumption that fatty acids are either 
synthesized by FASN (often termed de novo-synthesized) or imported. This assumption 
results in modeling the empirical isotopologue distribution as two sub-distributions, a “light” 
distribution representing imported fatty acid and a “heavy” distribution representing 
synthesized fatty acid. From these distributions, one determines the relative contribution of 
the de novo synthesis and import pathways to fatty acid pools. However, because elongation 
of imported fatty acids is not fundamentally incorporated into these models, their utility is 
largely restricted to fatty acids for which the contribution of elongation to the pool is 
minimal (e.g., 14- and 16-carbon species). Subsequent iterations of these models include 
single elongation of imported fatty acid species, extending utility to 18-carbon fatty acids 
(Lee et al., 1994b; Lligona-Trulla et al., 1997; Oosterveer et al., 2009). More recently, a 
MATLAB-based algorithm (termed convISA) was developed to perform ISA with the option 
of single elongation (Tredwell and Keun, 2015), and it has already allowed greater access to 
this methodology (Gelman et al., 2018; Lau et al., 2017; Yao et al., 2016). However, it is 
likely that very-long-chain fatty acid (VLCFA; 20 to 24 carbons) pools include multiply 
elongated fatty acids. This complexity makes modeling the metabolism of these fatty acid 
species difficult and often inaccurate when using ISA or other similar models, limiting 
interrogation of how these fatty acid pools are regulated. This is a critical gap in current 
methodology because VLCFAs play essential roles in signaling and membrane structure in 
eukaryotic cells (Sassa and Kihara, 2014; Vance and Vance, 2008).
To address this barrier in understanding cellular fatty acid metabolism, we developed Fatty 
Acid Source Analysis (FASA), an approach that models both single and multiple elongations 
of imported fatty acids in addition to modeling de novo synthesis and direct import. 
Application of FASA significantly increases accuracy when defining the sources of fatty 
acids contributing to the very-long-chain saturated, monounsaturated, and polyunsaturated 
fatty acid pools found within the cellular lipidome. In addition, application of FASA at 
metabolic and isotopic steady state revealed previously unmeasured aspects of fatty acid 
metabolism in cells. Examination of a cancer cell line demonstrated that upward of 80% of 
20- to 24-carbon saturated and monounsaturated fatty acid species can be products of the 
elongation machinery. Using FASA, we also provide evidence that the acetyl-CoA pools 
contributing to both fatty acid synthesis and elongation pathways can behave as a well-
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mixed pool. Finally, application of FASA to primary macrophages revealed that Toll-like 
receptor (TLR) signaling has profound effects on synthetic and elongation pathway 
utilization. Taken together, these studies demonstrate the development and application of this 
approach to interrogate underappreciated aspects of cellular fatty acid metabolism.
RESULTS
Current Models Fail to Accurately Model Fatty Acids More Than 18 Carbons in Length
Cells maintain their fatty acid composition through a complex mixture of synthesis, import, 
and modification (e.g., desaturation and elongation) pathways (Vance and Vance, 2008). 
Stable isotope labeling and subsequent modeling of isotopologue distributions of fatty acids 
using ISA and MIDA allow accurate identification of the sources of LCFAs contributing to 
the cellular lipidome. Using these approaches, one can distinguish LCFAs that were 
synthesized by FASN from LCFAs that were directly imported or imported and then 
elongated once (Lee et al., 1994a; Lligona-Trulla et al., 1997; Oosterveer et al., 2009; 
Tredwell and Keun, 2015). However, many fatty acids in the cellular lipidome, such as 
VLCFAs, can be subject to multiple elongation events (Vance and Vance, 2008). Thus, we 
sought to ask whether application of ISA would accurately model VLCFAs.
To address this, human lung cancer-derived H1299 cells containing a stably incorporated 
doxycycline-inducible shCON (designated H1299 shCON) were cultured in medium 
containing 2% fetal bovine serum (FBS), 100% U-13C6 glucose, and 100% U-13C5 
glutamine for 48 hr. After labeling, cellular lipids were derivatized, and isotopologue 
distributions for the resulting fatty acid methyl esters (FAMEs) were determined by gas 
chromatography-mass spectrometry (GC-MS). For this and all other experiments, the natural 
abundance of carbon, hydrogen, and oxygen isotopes was accounted for (see figure legends; 
STAR Methods). For each figure, isotopologue distribution data (before any correction for 
abundance of natural isotopes) are provided in Table S1. ISA was employed to determine the 
contribution of synthesis, import, and import with single elongation to the indicated cellular 
fatty acid pools. Note that, when performing ISA, we used convISA, a recent and publicly 
available MATLAB-based implementation of ISA (Tredwell and Keun, 2015). As expected, 
visual inspection revealed that ISA model fits were excellent for 14- to 18-carbon LCFA 
species (Figures 1A, S1A, and S1B). However, we observed that ISA model fits deteriorate 
as fatty acid carbon chains become longer (i.e., 20–24 carbons; Figures 1B, 1C, and S1D). 
For example, inspection of the best fit for the fatty acid 20:0 revealed a noticeable M+4 
abundance ISA could not account for (Figure 1B, blue bracket on isotopologue distribution). 
Best fits for 22:0 and 24:0 revealed that ISA had difficulty finding the true FASN-
synthesized (referred to hereafter as synthesized) distribution (Figures 1C and S1D, blue 
bracket on isotopologue distribution) and instead fit intermediate masses as the main 
components of the synthesized distribution (Figures 1C and S1D, red bracket). Similar 
results were seen with murine bone marrow-derived macrophages (BMDMs) and primary 
human fibroblasts (Figures S3A–S3C and S5A–S5C). Analysis of the sum of squared errors 
(SSEs) between the empirical isotopologue distribution and the ISA model fitting confirmed 
significant error in the modeled data for fatty acids longer than 18 carbons (Figure 1D). 
Similar SSE results were seen with murine BMDMs (Figure S3D). Taken together, these 
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data demonstrate that ISA provides accurate modeling of LCFAs containing up to 18 
carbons but becomes less accurate as the fatty acid chain length increases.
Development of FASA, a Model that More Accurately Defines VLCFA Metabolism in Cells
ISA modeling assumes that fatty acids are fully synthesized, directly imported, or imported 
and elongated once. Parameter D of ISA modeling represents the fractional contribution of 
13C-labeled metabolites to the lipogenic acetyl-CoA pool. Correspondingly, 1-D represents 
the fractional contribution of natural metabolites to the lipogenic acetyl-CoA pool. 
Parameter g(t) represents the percentage of a given fatty acid pool that has been synthesized 
at time t (Kelleher and Masterson, 1992; Kelleher and Nickol, 2015). Parameter g4(t) 
represents the percentage of a given fatty acid pool that has been elongated once from an 
unlabeled shorter fatty acid. 1-g(t)-g4(t) defines the unlabeled fraction of a given fatty acid 
pool. For simplicity, we designate g(t), g4(t), and 1-g(t)-g4(t) as S (de novo-synthesized by 
FASN), IE1 (imported-elongated once), and I (imported). Before steady state is achieved, the 
imported pool (I) is a mixture of newly imported and pre-existing fatty acids, whereas the 
IE1 pool is a mixture of newly imported and pre-existing fatty acids that have been elongated 
once (Buescher et al., 2015).
Elongation of fatty acids relies on the condensation of carbons from the acetyl-CoA pool. 
We reasoned that the intermediate masses observed in the isotopologue distributions of 
VLCFAs (see Figures 1B and 1C for examples) resulted from multiple rounds of enzymatic 
condensation of 13C-labeled carbons from the acetyl-CoA pool and that this accumulation of 
intermediate masses likely interferes with accurate model fitting using conventional 
approaches. To overcome this barrier in modeling, we created an approach, FASA, that 
allows fatty acids to be either synthesized (S), imported (I), or elongated (singly or multiply) 
from imported fatty acid species (designated IEn, where n is the number of elongations after 
import) as short as 14:0 (Figure 2A). Incorporation of the imported-elongated parameters 
(IEn) results in one additional distribution per two-carbon increase in length from 14:0.
FASA also allows direct modeling of the lipogenic acetyl-CoA pool. Multiple turns of the 
tricarboxylic acid (TCA) cycle can result in lipogenic acetyl-CoA that contains one carbon 
from a labeled metabolite and a second carbon from an unlabeled metabolite in a 
phenomenon we termed “label diffusion.” Label diffusion can cause an increased abundance 
of odd-numbered isotopologues and decreased even-numbered isotopologues compared with 
what would be expected without label diffusion, a phenomenon that has been reported 
previously (Collins et al., 2011) and that we have also observed in certain cases (e.g., Figure 
S6A). To ameliorate this issue, we designed FASA to allow the user to define whether to 
model the dilution of 13C-labeled metabolites into the lipogenic acetyl-CoA pool 
(parameters D and 1-D) or to model the frequency of lipogenic acetyl-CoAs with 0, 1, and 2 
13Cs using parameters D0, D1, and D2. The same D from ISA (the fractional contribution of 
13C-labeled metabolites to the lipogenic acetyl-CoA pool) can still be calculated from D0, 
D1, and D2 (STAR Methods), but this addition also allows the potential to account for and 
measure changes in label diffusion. For consistency, when applying FASA in this study, we 
modeled parameters D0, D1, and D2. To determine the metabolic parameter values (i.e., D0, 
D1, D2, S, I, IE1, etc.) that result in the best fit for a given isotopologue distribution, we 
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developed a MATLAB-based script that uses a constrained gradient descent optimization to 
minimize the SSE between the empirical and modeled isotopologue distributions for each 
fatty acid in each sample. Monte Carlo replicates with random parameter starting points 
were performed to ensure that the global minimum of the SSE function was found (STAR 
Methods).
Visual inspection of 14- to 18-carbon fatty acid isotopologue distributions using FASA 
revealed equivalent or slightly improved fits compared with ISA (Figures 2B, S1A, S1B, 
S2A–S2C, and S4A–S4C). Accordingly, model-derived parameters such as S, IE1, I, and D 
were nearly identical between ISA and FASA (Figures 2C, 2G, S1A, S1B, S2A–S2C, S3E, 
S4A–S4C, and S5E) for these LCFAs. Importantly, analysis of isotopologue distributions for 
VLCFAs with FASA resulted in significantly better visual fits compared with ISA, 
ameliorating the issues with modeling the intermediate masses (Figures 2D, S1C, S1D, 
S3A–S3C, and S5A–S5C). Model-derived parameters (e.g., S, I, and IE1) were significantly 
adjusted, and contributions of multiple elongations to the fatty acid pool were now 
quantifiable (Figures 2E, 2G, S1C, S1D, S3A–S3C, S3E, S5A–S5C, and S5E). For example, 
in 24:0, shorter imported fatty acids that had been multiply elongated made up a significant 
portion (≈35%) of the pool in H1299 shCON cells (Figure 2E). Similar results were seen 
with murine BMDMs (≈40%; Figure S3C) and primary human fibroblasts (≈35%; Figure 
S5C). Consistent with better visual fits, the SSEs were significantly lower for fatty acids 
containing 20 or more carbons when using FASA (Figures 2F, S3D, and S5D). Results from 
log-likelihood ratio tests also indicated that FASA’s superior fits for these longer fatty acids 
were not due to increased parameter number alone (p ≤ 0.05; STAR Methods; Table S2). 
Together, these results demonstrate the value of including parameters for multiple 
elongations when modeling fatty acids longer than 18 carbons.
When applying FASA to H1299 shCON cells, we observed that the model-derived values for 
D were consistent across all LCFA and VLCFA species measured (Figure 2G). Similar 
results for D were seen in studies of macrophages and primary human fibroblasts (Figures 
S3E and S5E). This observation for D is consistent with concept that the acetyl-CoA and 
malonyl-CoA pools available to both FASN and elongation machinery (i.e., ELOVL1-7) can 
be equivalently labeled from the isotope-labeled metabolite precursors (in this case, U-13C6-
glucose and U-13C5-glutamine). Thus, we conclude that the acetyl-CoA pool contributing to 
both the fatty acid synthetic and elongation pathways (the lipogenic acetyl-CoA pool) can 
behave as a single well-mixed pool rather than distinct pools with different contributions of 
isotope labels. Although spatially separated acetyl-CoA pools exist within the cell (e.g., 
cytosolic [Vance and Vance, 2008], endoplasmic reticulum [ER; Jonas et al., 2010], 
mitochondrial [Vance and Vance, 2008], peroxisomal [Wong et al., 2004], and nuclear 
[Bulusu et al., 2017]), these different pools are either isotopically equivalent to the lipogenic 
acetyl-CoA pool or do not significantly contribute to fatty acid metabolic processes under 
the conditions tested here.
To provide evidence that FASA can detect specific changes in elongation, we applied FASA 
to isotopologue distributions for LCFAs and VLCFAs from H1299 cells where ELOVL1 
expression was transiently silenced using small interfering RNAs (siRNAs). siControl- and 
siELOVL1-treated cells were cultured in medium containing 2% FBS and 100% U-13C6-
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glucose. Cells were collected for mRNA and fatty acid analysis after 24 hr and 48 hr of 
labeling, respectively. ELOVL1 preferentially elongates VLCFA and should have little effect 
on LCFA elongation, which is largely regulated by the elongase ELOVL6 (Vance and Vance, 
2008). Analysis of mRNA confirmed a significant decrease in ELOVL1 gene expression 
(≈10% of control; Figure S6B). A modest but statistically significant increase in ELOVL6 
was also seen, likely as a compensatory effect (Figure S6B). Importantly, analysis of fatty 
acid isotopologue distributions using FASA revealed that silencing of ELOVL1 had a 
significant effect on the contribution of elongation to the cellular 22:0 and 24:0 pool (Figure 
S6C). In contrast, the contribution of elongation to the 16:0, 18:0, and 20:0 pools remained 
unchanged (Figure S6C). These results provide proof of concept that FASA can be applied 
to isotope labeling studies to detect specific changes in the utilization of cellular elongation 
pathways.
Inclusion of Parameter Constraints in FASA to Accommodate Polyunsaturated Fatty Acid 
Elongation
In mammals, essential polyunsaturated fatty acids (PUFAs) are not synthesized de novo (Le 
et al., 2009), and mammalian cells rely on import of these fatty acids from the diet (e.g., 
18:2n-6, 18:3n-3). Upon import, these fatty acids are elongated and/or desaturated to create a 
wide variety of requisite PUFAs (Vance and Vance, 2008). Because FASA allows for import 
and multiple elongation of fatty acids, we thought it possible that FASA could be applied to 
model elongation of PUFAs. Furthermore, we designed FASA to allow users to easily 
constrain model parameters to any specific value a priori as part of the input data Excel file. 
For example, when analyzing n-6 or n-3 PUFAs, one can set the S parameter (representing 
synthesized fatty acids) to zero because mammalian cells cannot synthesize these fatty acids 
de novo. One can also set the D0, D1, and D2 parameters to values determined from other 
more abundant fatty acids (for instance, using D0, D1, and D2 defined from 16:0 to model 
other fatty acids in the same sample). Although defining these parameters a priori adds 
additional assumptions, it effectively constrains the parameter space when only a few 
isotopologues are measurable, a common occurrence with PUFAs.
With these concepts in mind, we asked whether FASA would be capable of modeling n-6 
PUFA metabolism in cells. Linoleic acid (18:2n-6) is an essential PUFA that serves as the 
substrate for synthesis of other n-6 PUFAs via the actions of elongases and desaturases 
(Figure 3A; Vance and Vance, 2008). Therefore, we set the parameters for synthesis (S) and 
import-elongation from 14 and 16 carbons (IE2–IE3 for 20-carbon PUFA and IE3–IE4 for 
22-carbon PUFA) to zero. We also fixed the D0, D1, and D2 parameter values to reflect the 
parameter values obtained from 16:0. Visual inspection of FASA-generated isotopologue 
distributions for 22:4n-6 from H1299 shCON cells, BMDMs, and primary human fibroblasts 
revealed good fits compared with empirical data (Figures 3B, S7A, and S7C). For the three 
cell types tested, we found that a sizeable portion of the 22:4n-6 pool was generated via 
elongation (IE1 ≈25%-40% and IE2 ≈0%–10%; Figures 3C, S7A, and S7C).
Interestingly, we observed evidence of double elongation into the 20:3n-6 pool for all three 
cell types tested. Inspection of the empirical 20:3n-6 isotopologue distributions revealed the 
presence of an M+4 isotopologue (Figures 3D, S7B, and S7D), indicating a non-zero 
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contribution of double elongation to the 20:3n-6 pool despite an expectation of only single 
elongation. Therefore, we included an additional import-elongation distribution for this 
PUFA to accommodate elongation from 16 carbons when applying FASA (Figures 3A, 3D, 
S7B, and S7D). For the three cell types tested (H1299 shCON cells, murine BMDMs, and 
primary human fibroblasts), a notable portion of the 20:3n-6 pool was generated through 
elongation (IE1 ≈5%–35% and IE2 ≈5%–15%; Figures 3E, S7B, and S7D). The origin of 
16:2n-6 in these cells remains to be determined, and it is possible that plant-derived 16:2n-6 
could be present in our culture media. Alternatively, it may be that some percentage of 
18:2n-6 is shortened into a 16:2n-6 species before subsequent elongation. Additionally, it is 
not clear which enzyme(s) would be involved in the elongation of 16:2n-6. One or more 
ELOVLs are likely candidates; however, for simplicity in our elongation diagrams (Figures 
2A and 3A), we only list specific ELOVLs known to have strong activity for a given 
substrate (Sassa and Kihara, 2014). Taken together, these studies provide proof of concept 
that FASA can model PUFAs and can measure underappreciated aspects of fatty acid 
metabolism within a cell.
Determining Minimum Parameter Levels for Accurate Modeling
One limitation of any stable isotope modeling approach for lipid metabolism occurs when 
isotope labeling of the lipid of interest is low. As the amount of stable isotope label in the 
acetyl-CoA pool decreases, the synthesis (S) and import-elongated (IEn) distributions will 
approach the imported (I) distribution, making model fitting progressively more difficult. 
Therefore, we sought to determine the minimal amount of labeling of the acetyl-CoA pool 
(parameter D when 13C-enrichment in the labeled metabolites (e) is at or near 100%) 
required for FASA to effectively fit the distributions in LCFA and VLCFA isotopologue 
distributions.
To this end, H1299 shCON cells were cultured for 48 hr in medium containing 2% FBS and 
increasing percentages of U-13C6 glucose and U-13C5 glutamine. After labeling, the cells 
were collected, and fatty acid isotopologue distributions were determined. Modeling of 
isotopologue distributions with FASA revealed that model parameter D behaved in a linear 
fashion with respect to the percentage of 13C-labeled metabolites in the medium down to D 
≈30% for 14:0–24:0. Shorter fatty acids remained linear down to D ≈ 10%, the lowest 
labeling level tested (Figure S8A). In most cases, the S and I model parameters (FASN-
synthesized and imported, respectively) were consistent as long as D was in the linear range 
described above (Figure S8B). However, for elongation parameters (IEn), we observed that a 
variable level of labeling in the lipogenic acetyl-CoA pool was required for consistent 
determination. For example, when examining the elongation parameters of 22:0, we 
observed that the IE1 and IE4 parameters were consistent down to a D of ≈40% (Figure 
S8B). In contrast, IE2 and IE3 required higher levels of labeling to achieve consistent values 
(D ≈50%) (Figure S8B). From these studies, we conservatively conclude that FASA will 
most consistently model 14- to 24-carbon fatty acids when the lipogenic acetyl-CoA pool is 
labeled to at least 50% (Figures S8C and S8D).
We further explored this issue using in silico-based sensitivity analyses to determine the 
robustness of FASA to variations in input data and noise. To test D, a realistic parameter set 
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for fatty acid sources was chosen for each fatty acid length (based on empirical data), and D 
was varied from 5% to 80% (STAR Methods). Theoretical isotopologue distributions were 
generated from the parameter sets, and multiple realizations of Gaussian noise were added to 
each theoretical isotopologue distribution. Each of these realizations was analyzed by FASA. 
For both expected and high noise levels, nearly all parameters were well-defined (≤10% 
bias) in our biologically relevant test cases when D was greater than or equal to 50%, 
agreeing with our in vitro experiment above (Figure S9 and data not shown). We observed 
somewhat higher biases (10%–45%) for a few parameters. However, these larger biases 
occurred in lower abundance imported-elongated parameters that are generally combined 
with larger, more stable parameters in subsequent analyses (see below). We also found that 
increasing D above 50% lowered the bias of these outliers to below 10%.
Similar in silico tests were run to determine accuracy of fits when varying S and IEmax (the 
imported-elongated distribution with the most elongations) values. When testing these 
parameters, empirically derived intermediate values for D0, D1, and D2 were held constant, 
whereas S or IEmax were varied from 1%–90% or 0.1%–8%, respectively (STAR Methods). 
Under expected noise conditions, all parameters were well-defined (≤10% bias) when S ≥ 
5%, and under high noise conditions, the large majority of parameters had low to modest 
bias (≤25%) when S ≥ 5% (Figure S10 and data not shown). When IEmax ≥ 1%, all 
parameters were well-defined (≤10% bias) under expected noise conditions, and under high 
noise conditions, there were only a few outliers (10%–30% bias; Figure S11 and data not 
shown). In sum, we provide in vitro and in silico evidence that FASA parameters can be 
determined accurately for realistic noise levels and parameter values.
Application of FASA Reveals a Significant Contribution of Elongation Pathways to Fatty 
Acid Homeostasis
Translation of labeling data and modeling parameters into metabolic information is complex 
and depends on both the system and the labeling conditions (Buescher et al., 2015). 
Interpretation of FASA parameters as well as parameters from many other stable isotope 
labeling models is simplified when measurements are made at isotopic and metabolic steady 
state (iSS and mSS, respectively) (Buescher et al., 2015). A metabolite pool reaches iSS 
when its isotopologue distribution remains constant over time, whereas a metabolite pool 
reaches mSS when its size and fluxes remain constant over time (Buescher et al., 2015). Key 
advantages for applying FASA at iSS and mSS are that pre-existing, and therefore unlabeled, 
pools of fatty acids have been diluted out, and fluxes are constant. This allows unambiguous 
identification of unlabeled fatty acids as imported and allows one to determine the relative 
contribution of different sources to a given fatty acid pool (e.g., FASN-synthesized versus 
imported) (Buescher et al., 2015). Although these steady-state conditions are hard to ensure 
in any system, culturing cells for an extended period of time in the presence of stable isotope 
metabolites can approximate iSS and mSS (Buescher et al., 2015).
To study cells at iSS and mSS, H1299 cells were cultured in medium containing 5% FBS 
and 100% U-13C6-glucose for 5 days (approximately 5 cell divisions). The culture medium 
was refreshed every 12 hr, and cells were maintained in a subconfluent state. After 
collection, fatty acid isotopologue distributions were determined and modeled using FASA. 
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In line with our previous data (Figure 2G), D was remarkably consistent across all measured 
saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs; Figure 4A). Analysis 
of individual SFA and MUFA species from 16 to 24 carbons in length revealed that 
individual fatty acid pools are indeed an admixture of imported, synthesized, and imported-
elongated fatty acids (Figure 4B and data not shown). For example, modeling of the 20:0 
fatty acid pool indicates that ≈45% of the pool is derived from fatty acids that were 
synthesized by FASN and subsequently elongated, ≈15% is directly imported, and ≈40% of 
the 20:0 fatty acids were imported as shorter species (14:0, 16:0, or 18:0) and then subject to 
elongation (IE1 ≈20% [18:0 to 20:0], IE2 ≈ 15% [16:0 to 20:0], and IE3 ≈5% [14:0 to 
20:0]). These results underscore the importance of using a model that includes the 
possibility of multiple elongations to imported fatty acids, particularly when analyzing 
VLCFAs.
In classical ISA, S and I at mSS and iSS represent the contribution of de novo synthesis and 
import to a particular fatty acid pool (Kelleher and Nickol, 2015; Metallo et al., 2011). In 
addition, the ratio of S to I represents the ratio of the synthetic and import fluxes when two 
additional assumptions are made: that de novo synthesis and import are the only 
contributions to the pool and that there is no preferential loss from the pool (Buescher et al., 
2015). These concepts can be generalized in FASA; the contribution of import and 
elongation to a particular fatty acid pool with 18 or more carbons can be determined by 
comparing I with the sum of the other source parameters (Figure 4C). Relative fluxes of 
import and elongation can also be determined when the same additional assumptions are 
made. Note that, for fatty acid pools that are direct products of desaturation instead of 
elongation (e.g., 18:1n-9), elongation contribution can still be determined, but import will 
include both direct import and import followed by desaturation. Additionally, although the 
final product of FASN is primarily 16:0, it has been reported to produce 14:0 and 18:0 at 
lower frequency (Vance and Vance, 2008; Wakil, 1989). For simplicity, we assume that, with 
the exception of the 14:0 pool, all FASN products are 16:0 (STAR Methods).
Summation of the fatty acids subject to synthesis and elongation in the SFA and MUFA 
pools revealed that the elongation pathways contributed roughly 50%–75% of the 18-carbon 
species in the cell and 80%–95% for 20- to 24-carbon species (Figure 4D). Examination of 
select n-6 PUFAs revealed higher variation in elongation contribution, with approximately 
15% of 20:3n-6 and 70% of 22:4n-6 having been elongated once or twice. These data 
demonstrate that elongation pathways can be an important metabolic conduit to meet a cell’s 
fatty acid requirements.
Application of FASA to Pre-iSS and/or mSS Fatty Acid Pools
Although FASA can provide a significant amount of information about fatty acid origin and 
relative flux at iSS and mSS, it is difficult to achieve and/or maintain iSS and mSS for the 
required labeling period (often multiple days) in many model systems (Buescher et al., 2015; 
Metallo et al., 2011). Thus, we sought to determine what biological information can be 
ascertained from application of FASA when cells have not yet achieved iSS and/or mSS in 
fatty acid pools. To this end, H1299 shCON cells were treated with doxycycline for 96 hr; in 
the final 48 hr of doxycycline treatment, they were also labeled in medium containing 5% 
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FBS, 100% U-13C6-glucose, and 100% U-13C5-glutamine. H1299 shCON cells divide 
approximately twice over this labeling period; this time period is not sufficient to achieve 
iSS for the fatty acid pools of the cells (Metallo et al., 2011). After 48 hr of labeling, cells 
were counted on-plate, collected, and analyzed for fatty acid content. Note that, when 
applying ISA, FASA, or other similar models, we make the assumption that the lipogenic 
acetyl-CoA pool reaches iSS quickly compared with the total labeling time. Multiple 
relevant central carbon metabolites (including citrate) have been shown to approach isotopic 
steady state at or before 2 hr of labeling (Yoo et al., 2008), supporting the validity of this 
assumption for a 48-hr labeling period (STAR Methods).
Before iSS and/or mSS in the fatty acid pools is achieved, it is difficult to use FASA or other 
isotope labeling analyses to determine the contribution of import to a given fatty acid pool 
because the unlabeled fatty acid population of the cell is an unknown mixture of newly 
imported and pre-existing unlabeled fatty acids. However, application of FASA before iSS 
and/or mSS is achieved in fatty acid pools still allows one to quantify the accumulation of 
both de novo-synthesized (from FASN activity) and elongated fatty acids during the labeling 
period. For example, if pool size and cell numbers are known, then one can calculate the 
accumulation of elongated fatty acid in any measured fatty acid pool over the labeling period 
(STAR Methods). The results for this type of analysis for 20:3n-6 and 22:4n-6 are shown in 
Figure 5A.
If data exist for a large number of fatty acids in a single pathway, then one can go a step 
further and calculate the contribution of each pathway step to accumulated fatty acids. For 
example, FASA parameters determined before fatty acid pools have reached iSS and/or mSS 
can be used to determine the accumulation of SFA and MUFAs in the cellular lipidome that 
were directly elongated from 18 to 20 carbons. This includes elongation products that 
remained in the 20-carbon fatty acid pools and those that were subject to subsequent 
elongations and/or desaturation events. In this process, we first determine all SFAs and 
MUFAs that would have been subject to elongation from 18 to 20 carbons (Figure 5B). Note 
that SFA and MUFA of the same length are combined in this analysis because the relevant 
elongases acting on these fatty acids are similar (Sassa and Kihara, 2014; Vance and Vance, 
2008). Multiplying these values by the final measured amount of each fatty acid pool 
divided by the average cell number on the plate during the entire isotope labeling period 
results in the contributions of each fatty acid to the total accumulation of 18 to 20 SFA and 
MUFA elongation products over the labeling period (Figure 5C). Summing these individual 
contributions provides the total accumulation of 18 to 20 SFA and MUFA elongation 
products (in nmol per 1e6 cells) during the labeling period (Figure 5D). This process can be 
repeated similarly for other elongation steps and for de novo synthesis to define the 
contribution of the elongation and synthetic machinery to fatty acid accumulation in the cell 
over the labeling time (Figures 5E and 5F; STAR Methods). Note that, for simplicity, we 
assume that, with the exception of the 14:0 pool, all FASN products are 16:0 (STAR 
Methods).
In proof-of-concept studies, we applied this approach to H1299 cells that have the sterol 
regulatory element binding protein (SREBP) transcriptional axis acutely disrupted using a 
doxy-cycline-inducible shRNA targeting the SREBP chaperone SCAP (Abel et al., 2013). 
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SREBPs are master transcriptional regulators of lipid homeostasis and are reliant on SCAP 
for their proper function (Horton et al., 2002; Matsuda et al., 2001). Cells were treated with 
doxycycline for 96 hr; in the final 48 hr of doxycycline treatment, they were also labeled in 
medium containing 5% FBS, 100% U-13C6-glucose, and 100% U-13C5-glutamine. After 48 
hr of labeling, cells were collected for gene expression analysis or counted on-plate and 
collected for fatty acid analysis. The knockdown efficiency for SCAP was approximately 
90% of control cells, and accordingly, the expression of SREBP target genes involved in 
fatty acid metabolism was also significantly decreased (Figure 6A) (Horton et al., 2002). 
Application of FASA, followed by the analytical approach described in Figures 5B–5D, 
demonstrated that loss of SREBP activity significantly decreased the accumulation of SFA 
and MUFAs that were synthesized by FASN and/or acted on by the elongation machinery 
(Figures 6B and 6C). A less significant effect on PUFA elongation was observed (Figures 
6A and 6D). These data provide proof of concept that application of FASA before fatty acid 
pools have reached iSS and/or mSS can reveal an integrated picture of the accumulation of 
synthesized and elongated fatty acids in response to perturbations.
Macrophages Specifically Reprogram Elongation in Response to Inflammatory Stimuli
Macrophages rapidly reprogram their lipid metabolism in response to inflammatory signals. 
These changes in metabolism are critical for proper differentiation and function (O’Neill and 
Pearce, 2016; York et al., 2015; Zhang et al., 2017). To date, little is known about how TLR 
signals influence the flow of fatty acids through elongation pathways. To investigate this 
question, BMDMs were stimulated with a panel of TLR agonists (Pam3CSK4 [TLR2], 
poly(I:C) [TLR3], or lipopolysaccharide (LPS) [TLR4]) for 48 h in medium containing 5% 
FBS, 100% U-13C6-glucose, and 100% U-13C5-glutamine. Analysis of fatty acid 
isotopologue distributions was performed using FASA. Confidence intervals for FASA 
parameters from macrophage experiments are provided in Table S3. Analysis of the FASA 
results revealed that TLR2 activation significantly increased the accumulation of SFA and 
MUFA that were generated through FASN and/or elongation machinery (Figures 7A and 
7B). In contrast, TLR3 stimulation resulted in the opposite metabolic program, with a 
profound decrease in the accumulation of SFA and MUFA generated through FASN and/or 
elongation pathways (Figures 7A and 7B). Interestingly, TLR4 stimulation produced more 
modest changes in accumulation through FASN and/or elongation pathways, resulting in an 
intermediate phenotype (Figures 7A and 7B).
Analysis of n-6 PUFAs revealed different metabolic reprogramming in response to these 
pro-inflammatory stimuli compared with SFA and MUFA (Figure 7C). TLR3 stimulation 
resulted in significant accumulation of elongated 22:4n-6, whereas TLR2 and TLR4 
stimulation resulted in minimal changes. All three TLR ligands resulted in a modest 
decrease in accumulation of elongated 20:3n-6. Of note, we found that gene expression 
studies alone would not be able to predict the complex accumulation pattern we observed in 
the reprogramming of fatty acid elongation machinery. For example, we found that TLR2 
activation resulted in similar or decreased expression levels of Elovl6 and Elovl3 (Figure 
7D), whereas FASA demonstrated significant accumulation of the products of these 
enzymes. In other cases, the gene expression and modeling data are concordant, such as 
upregulation of Elovl2 in response to TLR3 activation (Figure 7D) and the accumulation of 
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Elovl2 product 22:4 (Figure 7C). This provides evidence that FASA can reveal an integrated 
picture of different contributions to cellular fatty acid accumulation that can offer 
significantly more information than gene expression studies alone. We also asked whether 
FASA could model reprogramming of elongation during viral infections (Koyuncu et al., 
2013). BMDMs were challenged with the γ-herpesvirus MHV-68 (MOI = 1) in medium 
containing 5% FBS, 100% U-13C6-glucose, and 100% U-13C5-glutamine for 48 hr before 
lipids were collected and analyzed as above. We observed a pattern of synthesis and 
elongation similar to that of TLR3-stimulated BMDMs (Figures 7E and 7F and S12A). 
Likewise, gene expression studies also indicated a significant upregulation of Elovl2 in 
response to infection (Figure S12B), suggesting that reprogramming the elongation 
machinery is a physiologic response by the host to viral infection of cells. These data 
demonstrate that pro-inflammatory stimuli can reprogram the accumulation of fatty acids 
through synthetic and elongation pathways and that there is a high degree of specificity in 
these changes based on the type of inflammatory signal.
DISCUSSION
Understanding how lipids move through metabolic pathways under normal and disease 
states is of significant importance. Here we developed a model, FASA, that provides the 
ability to interrogate the contribution of synthesis, elongation, and import of fatty acids 
ranging from 14–24 carbons in length and 0–4 double bonds, covering the majority of fatty 
acids found in animal cells. FASA improves previous models such as ISA (or convISA) and 
MIDA by including several additional features relevant to modeling cellular fatty acid 
metabolism. First, we incorporate additional parameters not found in earlier models that 
allow single and multiple elongation of imported 14- to 22-carbon fatty acids. Second, we 
allow users to directly model the lipogenic acetyl-CoA pool. Third, we allow users to set 
multiple parameters a priori, facilitating the modeling of fatty acids (e.g., PUFA) and 
conditions (e.g., TLR3 stimulation) with little or no de novo synthesis. Finally, although 
FASA is a MATLAB algorithm, we have structured it so that minimal MATLAB experience 
is necessary to use it. The associated readme file contains instructions for use and 
descriptions of user handles. In addition, data inputs and outputs are in Excel format. The 
straightforward implementation of FASA will allow scientists with a wide range of 
computational backgrounds to utilize FASA to interrogate cellular fatty acid homeostasis. 
We anticipate that this model will lead to a better understanding of fatty acid metabolism in 
normal and disease states.
One of the largest challenges in stable isotope labeling is the appropriate interpretation of 
often complicated isotopologue distributions (Buescher et al., 2015). For FASA, examining 
cells at mSS and iSS will result in the simplest analysis. In this case, the key parameters for 
elongated fatty acids (18–24 carbons) are I and 1-I (Figure 4), which represent the 
contribution of import and elongation to a particular fatty acid pool, respectively. In many 
systems, although the lipogenic acetyl-CoA pool reaches iSS rapidly (Yoo et al., 2008), 
achieving mSS and iSS in fatty acid pools is not practically attainable. Information about the 
contribution of fatty acid import may be difficult to obtain under these conditions because of 
the confounding factor of cells containing pre-existing unlabeled fatty acid pools. 
Nevertheless, the accumulation of newly synthesized and imported-elongated fatty acids can 
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still be measured. These changes in accumulation provide useful biological information, but 
one must exercise caution when using changes in accumulation as a marker for changes in 
flux. In our studies, one cannot assess all of the modifications to fatty acids that may be 
occurring (e.g., β-oxidation) or the flow into unmeasured pools (e.g., SFA and MUFA, >24 
carbons). As a result of these confounding factors, it is possible, and indeed likely, that the 
accumulation described here will be an underestimation of the absolute flux in a given 
cellular system. Despite these concerns, FASA provides important insights into the lipid 
metabolic state of the cell, and we envision that future work focused on building kinetic 
models to define absolute fluxes of these enzymatic pathways will likely require information 
provided by FASA or another similar approach.
The above in silico tests demonstrate the importance of treating high-noise isotopologue data 
and/or low parameter values with some care (Figures S9–S11). Note that, for many 
parameters modeled in the in silico tests, high noise resulted in high relative SDs (RSDs) 
(particularly for parameters with small values), even when the average percent error (bias) 
was reasonable. Furthermore, in fatty acids where there is very little labeling (e.g., 18:2n-6 
and 20:4n-6 under the conditions tested here), small irregularities in the isotopologue 
distribution data (e.g., contaminants, ionization artifacts, error because of low signal) can 
potentially affect the modeling results. However, steps can be taken to ameliorate these 
issues. Cell culture conditions can potentially be modified to influence parameter values. If 
noise is relatively high, data collection protocols can be optimized to reduce error, and 
additional biological and/or technical replicates can be used to approach the true mean. 
When S < 5%, increasing the number of Monte Carlo replicates can help to ensure that the 
correct synthetic distribution (producing the global minimum SSE) is found.
Finally, one assumption common to ISA, MIDA, and FASA is that the acetyl-CoA pool 
contributing to lipogenesis has a uniform labeling pattern (Hellerstein and Neese, 1992; 
Kelleher and Masterson, 1992). FASN is the major source of 14- to 16-carbon SFAs, and the 
elongases (ELOVL1-ELOVL7) are the major source of 18- to 24-carbon fatty acids (Vance 
and Vance, 2008). Given that FASN is a cytosolic enzyme and that ELOVLs are embedded 
in the ER facing the cytosol, it is not unreasonable to assume that the cytosolic acetyl-CoA 
pool is the major lipogenic acetyl-CoA pool in the cell (Vance and Vance, 2008). Although 
other groups have identified conditions under which the mitochondrial (Wong et al., 2004), 
nuclear (Bulusu et al., 2017), or peroxisomal (Wong et al., 2004) acetyl-CoA pools can 
differ in labeling pattern from that of the cytosolic acetyl-CoA pool, the contribution of 
those organelles to de novo synthesis is often relatively small (Vance and Vance, 2008). 
Furthermore, the data presented here are consistent with the hypothesis that the lipogenic 
acetyl-CoA can behave as a single well-mixed pool. The D values calculated independently 
for 14-24-carbon SFAs and MUFAs are very similar, in agreement with the assumption 
(Figures 2G, 4A, S3E, and S5E). However, it is possible that this assumption would not hold 
true with all cell types or culture conditions. Consequently, it will be important to validate 
that analyzed fatty acids for a given sample yield similar D values when different conditions 
or experimental systems are used. We also show that successful application for VLCFAs 
requires a fairly significant level of labeling in the acetyl-CoA pool (≥50%) to obtain good 
fits for the data. Alternatively, it may be possible to lower the labeling requirements for the 
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acetyl-CoA pool by using modeling to improve the accuracy of isotopologue peak 
integration (Krämer et al., 2018; Stein, 1999).
In conclusion, here we provide a model, FASA, that allows indepth characterization of fatty 
acid synthesis, elongation, and import in cells. Using FASA, we have demonstrated that fatty 
acid elongation pathways significantly contribute to LCFA and VLCFA homeostasis in cells. 
We also show that these pathways are dynamically and differentially regulated by distinct 
inflammatory signals, suggesting an importance in regulating these pathways during 
responses to different classes of pathogens. As a result, we anticipate that application of 
FASA will be useful to a wide variety of fields endeavoring to elucidate how fatty acid 
homeostasis affects cellular fate and function.
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Steven J. Bensinger (sbensinger@mednet.ucla.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice—6- to 8-week-old male C57BL/6J mice were purchased from Jackson Labs. All 
animal protocols were approved by the UCLA Animal Research Committee.
Cell Lines and Primary Cells—All cell lines and primary cells were maintained at 37°C 
in a humidified incubator containing 5% CO2. All fetal bovine serum (FBS; Omega 
Biosciences, Atlanta Biosciences, VWR, HyClone) was heat-inactivated for 20 minutes at 
55°C before use in media.
Parental H1299 Cells: H1299 (human male non-small cell lung cancer-derived; also 
referred to as NCI-H1299) cells were purchased from ATCC. Cells were passaged in 
DMEM (Thermo Fisher) supplemented with 10% FBS, 100 U/mL penicillin (Thermo 
Fisher), and 100 mg/mL streptomycin (Thermo Fisher) or RPMI 1640 (Thermo Fisher) 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10 mM 
HEPES (Thermo Fisher). Cells were dissociated using trypsin-EDTA (Thermo Fisher).
293FT Cells: 293FT cells were provided by Dr. Harvey Herschman (UCLA). Cells were 
maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 1 mM sodium pyruvate (Thermo Fisher), 1% MEM non-essential amino acids 
(Thermo Fisher), and 6 mM glutamine (Thermo Fisher). Cells were dissociated using 
trypsin-EDTA.
Stable, Inducible shRNA H1299 Cells Lines: Short hairpin RNAs (shRNA) were 
synthesized by Integrated DNA Technologies. Oligonucleotides were annealed and ligated 
into the pENTR/H1/TO vector (Thermo Fisher) following the BLOCK-iT Inducible H1 
RNAi Entry Vector Kit manual. Resulting shRNA constructs were recombined into 
pLentipuro/BLOCK-iT-DEST (Abel et al., 2013) using Gateway LR Clonase II (Thermo 
Fisher) according to manufacturer instructions. The doxycycline induction of knockdown is 
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controlled by the Tet repressor (TetR) protein expressed from the pLenti0.3/EF/GW/IVS-
Kozak-TetR-P2A-Bsd vector (Abel et al., 2013).
Recombinant lentiviruses were packaged in 293FT cells according to manufacturer 
instructions by co-transfecting cells with lentivirus plasmid and packaging plasmids pLP1, 
pLP2, and pLP/VSV-G (Thermo Fisher) using FuGENE 6 (Promega) as a transfection 
reagent. Viral supernatants were collected 72 hours after transfection. Parental H1299 cells 
were first transduced with viral supernatant (pLenti0.3/EF/GW/IVS-Kozak-TetR-P2A-Bsd) 
for 72 hours, followed by selection with blasticidin (40 μg/mL; Invivogen). The resulting 
cells were then transduced with viral supernatant (pLentipuro/BLOCK-iT-DEST) for 72 
hours, followed by selection with blasticidin (40 μg/mL) and puromycin (4 μg/mL, Gemini).
The resulting H1299 shCON and H1299 shSCAP cell lines were passaged in DMEM 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 mM 
HEPES, and 2 μg/mL puromycin. Cells were dissociated using trypsin-EDTA.
Primary Human Fibroblasts: Primary human fibroblasts (male) were obtained from the 
Coriell Institute. The fibroblasts were passaged in DMEM supplemented with 10% FBS, 100 
U/mL penicillin, and 100 μg/mL streptomycin. Cells were dissociated using trypsin-EDTA.
Murine Bone Marrow-Derived Macrophages: Murine bone marrow-derived macrophages 
(BMDMs) were generated as previously described (Divakaruni et al., 2018; York et al., 
2015). Briefly, bone marrow cells were isolated from femurs of 6- to 8-week-old male 
C57BL/6J mice. Cells were treated with RBC lysis buffer (Sigma-Aldrich) for 5 minutes to 
remove red blood cells, centrifuged at 386xg for 5 minutes, and resuspended in BMDM 
culture medium. BMDM culture medium consisted of DMEM supplemented with 10% FBS, 
100 U/mL penicillin, 100 mg/mL streptomycin, 500 μM sodium pyruvate, 2 mM glutamine, 
and 5% conditioned medium containing macrophage colony stimulating factor (M-CSF) 
produced by CMG cells to induce differentiation to BMDMs (Takeshita et al., 2000). 
BMDMs were differentiated for 6 days prior to harvesting and re-plating for experiments, 
and medium was changed at Day 4 of differentiation.
METHOD DETAILS
Cell Culture—For experiments using the H1299 shCON line without induction, 13 × 103 
cells per well were plated in 24-well dishes at t = −16 h and changed into 0.6 mL labeling 
medium at t = 0 h. Labeling media consisted of DMEM (no glucose, glutamine, or phenol 
red; Thermo Fisher) supplemented with 2% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 10 mM HEPES, 2 μg/mL puromycin, 25 mM glucose, and 4 mM glutamine. 
The labeling media contained 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% 
U-13C6-glucose and U-13C5-glutamine (Cambridge Isotope Laboratories). At t = 48 h, cells 
were collected for fatty acid analysis using guanidine HCl.
For experiments using primary human fibroblasts, cells were plated into 12-well dishes 
using labeling medium (300 × 103 cells and 1 mL medium per well). Labeling medium 
consisted of DMEM (no glucose, glutamine, or phenol red) supplemented with 5% FBS, 100 
U/mL penicillin, 100 μg/mL streptomycin, 25 mM U-13C6-glucose, and 4 mM U-13C5-
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glutamine. After three days, the cells were collected for fatty acid analysis using guanidine 
HCl.
For siRNA knockdown experiments, 20 pmol of siRNA were combined with 2 mL of 
Dharmafect 4 transfection reagent in 200 μL of Optimem I (Thermo Fisher) defined medium 
in each well of a 12-well dish. A reverse transfection was carried out with 70 × 103 parental 
H1299 cells per well in RPMI supplemented with 10% FBS, 100 U/mL penicillin, and 100 
μg/mL streptomycin. 12 hours post-transfection, the medium was replaced with RPMI 1640 
(no glucose; Thermo Fisher) supplemented with 2% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 11 mM U-13C6-glucose. After 24 h, cells were collected for RNA analysis 
using TRIzol (Thermo Fisher). After 48 h, cells were collected for fatty acid analysis using 
guanidine HCl.
For experiments measuring parental H1299 cells at isotopic and metabolic steady state, cells 
were cultured in DMEM (no glucose; Thermo Fisher) supplemented with 5% FBS, 100 
U/mL penicillin, 100 μg/mL streptomycin, and 25 mM U-13C6-glucose. Medium was 
refreshed every 12 hours, and cells were passaged with trypsin-EDTA as necessary to 
maintain a sub-confluent state. After 5 days (approximately 5 cell divisions), the cells were 
collected for fatty acid analysis using trypsin-EDTA.
For experiments using H1299 shCON and shSCAP lines with induction, cells were induced 
in 10 cm plates at t = −48 h using DMEM supplemented with 10% FBS, 100 U/mL 
penicillin, 100 μg/mL streptomycin, 10 mM HEPES, 2 μg/mL puromycin, and 15 ng/mL 
doxycycline (Sigma-Aldrich). Cells were re-plated in 12-well dishes at t = −16 h (30 × 103 
cells per well) using DMEM supplemented with 5% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 10 mM HEPES, 2 μg/mL puromycin, and 15 ng/mL doxycycline. At t = 0 h, a 
set of replicate wells were counted on-plate, and the remaining wells were changed into 1 
mL of labeling medium. Labeling medium consisted of DMEM (no glucose, glutamine, or 
phenol red) supplemented with 5% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 
mM HEPES, 2 μg/mL puromycin, 25 mM U-13C6-glucose, 4 mM U-13C5-glutamine, and 15 
ng/mL doxycycline. At t = 48 h, cells were collected for RNA analysis using TRIzol or 
counted on-plate and collected for fatty acid analysis using guanidine HCl.
For experiments using murine BMDMs, at day 6 of differentiation (t = −48 h), macrophages 
were scraped, counted, and re-plated into 12-well dishes using BMDM culture medium 
(200×103 cells per well). At day 8 (t = 0 h), a set of replicate wells were counted on-plate 
then collected using guanidine HCl, while the remaining wells were changed into 1 mL of 
labeling medium containing no treatment, Pam3CSK4 (PAM3, 50 ng/mL; Invivogen), 
Poly(I:C) (PIC, 1000 ng/mL; Invivogen), LPS (50 ng/mL; Invivogen), or MHV-68 (MOI = 
1; Ting-Ting Wu (UCLA)). Labeling medium consisted of DMEM (no glucose, glutamine, 
or phenol red) supplemented with 5% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 
25 mM U-13C6-glucose, 6 mM U-13C5-glutamine, and 5% conditioned medium containing 
macrophage colony stimulating factor (M-CSF) produced by CMG cells. At day 9 (t = 24 h), 
cells were collected in TRIzol for RNA analysis. At day 10 (t = 48 h), cells were counted on-
plate and collected for fatty acid analysis using guanidine HCl.
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Gene Expression Analysis—Cells were collected in TRIzol and RNA was extracted 
using manufacturer’s protocols. cDNA was synthesized with High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) as per manufacturer’s instructions (700 ng/μL RNA 
per cDNA synthesis reaction). Quantitative PCR (qPCR) was conducted on the Roche 
LightCycler 480 using SYBR Green Master Mix (Kapa Biosciences) and 0.5 μmol/L 
primers. Relative expression values are normalized to control gene (36B4) and expressed in 
terms of linear relative mRNA values.
Cell Counting and Guanidine HCl Collection—Unless specified as counted on-plate, 
cells were counted using a Cellometer K2 (Nexcelom) after lifting from culture dishes. 
H1299 cells and primary human fibroblasts were counted using a 1:4 dilution of trypan blue 
(Thermo Fisher), while BMDMs were counted using a 1:1 dilution of acridine orange/
propidium iodide (Thermo Fisher, VWR). When counting on-plate, 1.25 μM Calcein-AM 
(final concentration; Santa Cruz Biotechnologies) was added to each well and incubated for 
15 minutes. The plates were then imaged on a Molecular Devices ImageXpress XL. 24 high 
magnification fluorescence images were captured for each well (11.9% of total well surface 
area) using a 10x objective (Nikon Plan Fluor, 0.3 NA). Cell number was assessed using 
MetaXpress Software with Powercore using the Multi-wavelength cell scoring module. For 
collection with guanidine HCl, cells were treated with 50 μL or 75 μL of 6 M aqueous 
guanidine HCl and transferred to glass tubes for derivatization with an additional 100 μL or 
150 μL of 3 M methanolic guanidine HCl (24-well plates and 12-well plates, respectively). 
Samples were prepared alongside internal standard curve samples made up of FAMEs (Nu-
Chek Prep).
Lipid Derivatization and GC-MS—For experiments using the H1299 shCON line 
without induction and for the siRNA experiments, fatty acid methyl esters (FAMEs) were 
prepared as described previously (York et al., 2015).
For experiments using the parental H1299 line at isotopic and metabolic steady state, 
FAMEs were prepared as described previously (Ichihara and Fukubayashi, 2010) with the 
following modifications. After derivatization, 2 mL of aqueous 0.04 N NaCl was added to 
each sample. FAMEs were then extracted twice with 2 mL of hexane. The combined organic 
layers were then dried (EZ-2 Elite) and reconstituted in 100 μL of hexane for GC-MS 
analysis.
For all other experiments, FAMEs were prepared as described previously (Argus et al., 
2017) with the following modifications. The final reaction volume of 725 μL contained 
10.5% acetyl chloride, 10% toluene, and 6% water in methanol (v/v). The reaction 
proceeded at 45°C for 24 h, and was neutralized with 775 μL of 0.87M sodium carbonate in 
water. After addition of 1 mL of hexane, inversion, and centrifugation, the organic layer was 
extracted and dried. The remaining FAMEs were redissolved in 250 μL of hexane for 
analysis by GC-MS.
An Agilent 7890A-5975C GC-MS was used for analyzing the parental H1299 line at 
isotopic and metabolic steady state; an Agilent 7890B-5977A GC-MS was used for all other 
experiments. Complete GC-MS configurations and running programs are available upon 
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request. Integration and quantification of all ions was performed on MassHunter 
Quantitative Analysis Program (Agilent Technologies, B.06.00). Fatty acid pool sizes were 
determined by taking the sum of the area under the curve (AUC) for all isotopologues of the 
molecular ion, normalizing to internal standard (19:0 methyl ester added before 
derivatization; Nu-Chek Prep), and comparing to a FAMEs internal standard curve.
FAMEs Identification and Quantitation—The FAMEs standards used in these studies 
were the GLC-96 mix, 18:1n-7, and 19:0 (Nu-Chek Prep). FAMEs in biological samples 
were identified by molecular ion m/z (unit mass) and retention time compared to known 
standards. The only exception to this was two 20:1 isomers (distinct from 20:1n-9) in 
experiments related to Figures 5, 6, and 7 and S12. These analytes were identified as 20:1 
isomers by molecular ion m/z (unit mass) and the proximity of their retention times to that 
of the 20:1n-9 standard. In these applications of FASA (Figures 5, 6, and 7 and S12), all 
20:1 isomers were binned because specific isomer identification was unnecessary.
Given the large number of isotopologues quantified for each fatty acid, some at low 
abundance, it is possible that automated peak integration would quantify contaminants 
instead of or in addition to target compounds. To minimize the likelihood of this type of 
error in our isotopologue distributions, we visually inspected relevant extracted ion 
chromatogram peaks for every fatty acid in each sample, mock reaction, and calibration 
curve point to find and exclude potential contaminants whenever possible. In the rare case of 
coeluting contaminants, specific isotopologues were either flattened to zero (when the 
contaminant dwarfs a low abundance isotopologue) or not changed (when removal of the 
entire isotopologue affects the distribution more than the inclusion of the contaminant). SFA 
and MUFA isotopologues were normally collected up to M+(N+1), where N is the number 
of carbons in the fatty acid. In Figures 4 and S6, some fatty acids were collected up to M+N, 
M+(N-1), or M+(N-2). Given the very low predicted abundance at these ions, we do not 
anticipate their exclusion changes the results in any significant way. PUFA isotopologues 
were collected up to M+4 or M+6, depending on the fatty acid and experiment.
Correction for Natural Isotope Abundance—Correction for natural isotope 
abundance was performed using a matrix-based “skewed” correction algorithm (Midani et 
al., 2017) developed in-house. The following values were used for the natural abundance of 
stable isotopes: 1H = 0.999885, 2H = 0.000115, 12C = 0.9893, 13C = 0.0107, 16O = 0.99757, 
17O = 0.00038, 18O = 0.00205 (Midani et al., 2017). The following carbon abundances were 
used for stable isotope labeled metabolites according to manufacturer information: 12C = 
0.01, 13C = 0.99. Correction was applied to raw AUC values, and negative values were 
flattened to 0 (Moseley, 2010). For the ISA versus FASA comparisons (Figures 1, 2, S1–S5), 
the ELOVL1 knockdown (Figure S6), and the initial PUFA figures (Figures 3, S7), all 
isotope corrections (carbon, hydrogen, and oxygen) were performed before ISA and FASA 
analysis (including correction for 12C in stable isotope-labeled metabolites). In all other 
figures, isotope corrections for hydrogen and oxygen were performed before FASA analysis 
and carbon isotopes (both 13C from naturally occurring metabolites and 12C in stable 
isotope-labeled metabolites) were accounted for as part of FASA analysis (see parameters q 
and e below).
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Application of convISA—MATLAB .p files for convISA (Tredwell and Keun, 2015) 
were graciously shared by Dr. Hector Keun. Additional code was generated in-house to 
facilitate data input and output. The two parameter setting (“D” and “g(t)”) was used for 
14:0 and the three parameter setting (including a distribution for imported-elongated once, 
“elong”) was used for other fatty acids. Other user-defined parameters were as follows: 
AcCoAlabels = 2, deriv = ‘me’, raw = 0, weighted = 0, CI = 0, x0 = [.5,.05,.2].
Fatty Acid Source Analysis - FASA—In utilizing FASA, an isotope of carbon (13C) 
must be used as the label atom. In this paper, all isotopologue distribution data came from 
FAMEs. When isotopologue distribution data comes from FAMEs, all non-carbon natural 
isotope abundances must be corrected for before application of FASA, while all carbon 
natural isotope abundances (for label and natural carbons) can be corrected for before 
application of FASA or accounted for during the application of FASA. Note that if all carbon 
natural isotope abundances are corrected before using FASA, parameters q and e (see below 
for definitions) should be should be set at 0 and 1, respectively, when applying FASA.
In FASA, the total isotopologue distribution of a fatty acid with N total carbons, FN, is 
modeled as a weighted mixture of multinomial distributions: fully synthesized, CN, 
imported, BN, and several imported-elongated distributions, EN,i (Equation 1).
FN(n ∣ q, S ,D ) = S ∗ CN(n ∣ D ) + I ∗ BN(n ∣ q) + ∑
i = 1
M
IEi ∗ EN, i(n ∣ i, q,D ) (Equation 
1)
The synthesized, imported, and imported-elongated multinomial distributions are functions 
of the 13C abundance in natural metabolites (q), the isotopologue distribution of lipogenic 
acetyl-CoA (D ), and for imported-elongated distributions, the number of elongations (i). The 
parameter q can be set a priori or can be calculated from control cell lines grown with 
unlabeled media using maximum likelihood estimates. The multinomial distributions are 
scaled using the relative abundance of each fatty acid source (S , Equation 2) and summed to 
produce the total isotopologue distribution FN.
S = [S, I, IE1,…, IEM], whereM =
N − 14
2 (Equation 2)
S and I represent the proportion of a fatty acid pool that is fully synthesized and imported, 
respectively. IEi represents the proportion of a fatty acid pool that results from shorter 
imported fatty acids that have been elongated by i acetyl-CoAs. In this model, we do not 
consider elongation of fatty acids shorter than myristate (14:0). Small corrections are made 
to account for the possible incorporation of 13C in the methylation of fatty acids in GC-MS 
processing using q.
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To account for the possibility of label diffusion, the isotopologue distribution of the 
lipogenic acetyl-CoA pool is directly modeled, with D0, D1, and D2 representing the relative 
abundance of acetyl-CoAs containing 0, 1, or 2 13Cs (Equation 3).
D = [D0,D1,D2] (Equation 3)
Note that if all carbon natural isotope abundances (for label and natural carbons) have been 
corrected for before application of FASA, D  represents the carbon natural isotope 
abundance-corrected lipogenic acetyl-CoA pool.
D, the percent contribution of 13C-labeled metabolites to the lipogenic acetyl-CoA pool, can 
be calculated as follows (Equation 4).
D =
.5D1 + D2 − q
e − q (Equation 4)
Parameter e represents the 13C enrichment for each labeled metabolite used and is known a 
priori. This equation is valid when all labeled metabolites are uniformly labeled.
Imported fatty acids can be modeled as a binomial with N trials and success rate q, BN(n|q), 
as each carbon has an independent probability q of being 13C. Because synthesized fatty 
acids are built using 2-carbon blocks of acetyl-CoA, that distribution is modeled as a sum of 
N/2 2-carbon-units, each described as i.i.d. random variables A(D ) (Equation 5).
CN(D ) = ∑
1
N
2
[A(D )], whereA(n ∣ D ) =
D0 if n = 0
D1 if n = 1
D2 if n = 2
(5)
The multinomial distribution of an N-carbon fatty acid after undergoing i elongations, EN,i, 
is the sum of the binomial distribution of the imported FA, and a “synthesized” distribution 
of i acetyl-CoAs (Equation 6).
EN, i(i, q,D ) = BN − 2 ∗ i(q) + Ci ∗ 2(D ) (Equation 6)
Based on this model, our distributions are defined by the (M+6)x1 parameter vector 
B = [q,D0,D1,D2, S, I, IE1,…IEM]. Note that because the elements of S  and D  each must 
sum to 1, optimizations must be constrained. We enforce this constraint as follows 
(Equations 7 and 8):
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D2 = 1 − D0 − D1 (Equation 7)
IEM = 1 − S − I − ∑
i = 1
M − 1
IEi (Equation 8)
Therefore, optimizations are performed over the (M+4)x1 parameter vector 
b = [q,D0,D1, S, I, IE1,… . IEM‐1]. Maximum likelihood estimates are acquired for b , using a 
modified gradient descent algorithm. To ensure convergence to the global maximum instead 
of local maxima, each dataset is fit multiple times with random initial conditions.
In addition, this model allows for fixing parameter elements of b  which are known a priori, 
and will not be fit by the iterative algorithm. The most common parameter to fix will be 
background 13C abundance (q). We also allow for D  and any element of S  to be fixed based 
on data or a priori knowledge of metabolic pathways; this allows extension of FASA to fatty 
acids with little or no synthesis. Note that when fixing elements of S , the rightmost element 
of S  which is not held constant is constrained such that the elements of S  sum to 1.
If label diffusion is assumed to be zero, D  can be simplified to D and 1-D. To accomplish 
this, D1 and D2 become functions of D0, q, and e as follows (Equations 9–11):
D1 = (1 − D)[2q(1 − q)] + (D)[2e(1 − e)] (Equation 9)
D2 = 1 − D0 − D1 (Equation 10)
WhereD =
D0 − (1 − q)
2
(1 − e)2 − (1 − q)2
(Equation 11)
Note that if FASA is constrained to disallow label diffusion, all labeled metabolites used 
must be uniformly labeled.
In silico Tests of FASA—To test the robustness of FASA to variations in input data and 
noise, we performed in silico tests on the model. 14-to 24-carbon fatty acids with the 
possibility of de novo synthesis (representing SFA and MUFA) were tested independently. 
To test D, realistic parameter sets for fatty acid sources were chosen for each fatty acid 
length (based on empirical data, see Table S5 for values) while D was varied between 5%–
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80% (assuming no label diffusion). To test S, realistic parameter sets for D0, D1, D2, and 
fatty acid sources were chosen for each fatty acid length (based on empirical data, see Table 
S5 for values) while S was varied from 1%–90%, depending on observed ranges for each 
fatty acid. As S varied, I responded, while the IE parameters were kept constant. To test 
IEmax (the IE parameter with the most elongations), realistic parameter sets for D0, D1, D2, 
and fatty acid sources were chosen for each fatty acid (based on empirical data, see Table S5 
for values) while IEmax was varied from 0.1%–8%. As IEmax varied, S responded, while I 
and the remaining IE parameters were kept constant.
For each theoretical isotopologue distribution, 25 realizations of Gaussian noise were 
simulated at two noise levels (2% or 10% relative standard deviation – see “Confidence 
Interval Determination” section below for additional information on the choice of these 
values). Each of these “noisy” datasets was then analyzed independently by FASA. “Bias” 
represents the average of the percent errors between the fitted parameter values and the true 
parameter value. “RSD” represents the relative standard deviation of the fitted parameter 
values.
Steady State and FASA Parameter Definitions—We define metabolic steady state 
(mSS) as the point at which per cell fluxes and pool sizes for a given metabolite remain 
constant for the average cell in a population (Buescher et al., 2015). We define isotopic 
steady state (iSS) as the point at which the isotopologue distribution remains constant for a 
given metabolite (Buescher et al., 2015). mSS and iSS for fatty acids can be approximated 
by culturing cells in a sub-confluent state in stable isotope-labeled media for a period of time 
that is sufficient for the original fatty acids to be diluted out (Buescher et al., 2015; Metallo 
et al., 2011). In an idealized system (mSS, no fatty acid losses, acetyl-CoA pool reaches iSS 
within a few hours), 5 cell divisions is sufficient to dilute pre-existing fatty acid contribution 
to below 5%. In practice, losses may cause iSS to be reached more quickly.
For FASA at mSS and iSS, I represents the contribution of import for a given fatty acid. If 
fatty acid shortening is non-negligible, I will be a mixture of directly imported fatty acid and 
imported-shortened fatty acid.
Variable FASN Products—Though the final product of FASN is primarily 16:0, it has 
been reported to produce 14:0 and 18:0 at lower frequency (Vance and Vance, 2008; Wakil, 
1989). One challenge this creates is the inability of ISA and FASA to differentiate certain 
synthesized origins (e.g., a FASN-synthesized 18:0 from a FASN-synthesized 16:0 that is 
subsequently elongated). For simplicity, we assume that with the exception of the 14:0 pool, 
all FASN products are 16:0. As a result, at iSS and mSS, for 16:0 and 16:1n-7, IE1 will be an 
underestimate of the contribution of elongation and S will be an overestimate for the 
contribution of synthesis. For 18:0 and 18:1n-9 at iSS and mSS, 1-I will overestimate the 
contribution of elongation. 18:1n-7 does not have this issue because it is a direct elongation 
product of 16:1n-7.
When applying FASA before fatty acid pools have reached iSS and mSS, calculation of the 
accumulation of FASN products will not be affected, as we assume that any molecule 
comprised of all carbons from the lipogenic acetyl CoA pool was synthesized by FASN 
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(regardless of whether the direct FASN product was 14:0, 16:0, or 18:0). The accumulation 
of 14 to 16 elongation products (SFA+MUFA) will be underestimated because our 
calculations do not include the elongation of FASN-synthesized 14:0. The accumulation of 
16 to 18 elongation products (SFA+MUFA) will be overestimated because our calculations 
include direct FASN synthesis of 18:0.
Interpretation of D—In both ISA and FASA, D represents the percent contribution of 
13C-labeled metabolites to the lipogenic acetyl-CoA pool. We make the assumption that the 
lipogenic acetyl-CoA pool reaches iSS relatively quickly compared to total labeling time. 
One group demonstrated that ISA can be applied after 6 hours of labeling, with multiple 
relevant central carbon metabolites (including citrate) approaching isotopic steady state at or 
before 2 hours of labeling (Yoo et al., 2008). Furthermore, ISA is routinely applied after 24 
hours of labeling (Green et al., 2016; Parker et al., 2017). As a result, we do not believe our 
application of FASA after 48 hours of labeling is problematic, and we anticipate that FASA 
could be applied after shorter periods of labeling as well.
Note that for both ISA and FASA, when the acetyl-CoA pool reaches iSS, D represents both 
direct and indirect contributions (e.g., 13C glucose to 13C amino acids to 13C acetyl-CoA). In 
addition, the ratio of D to 1-D represents the ratio of the fluxes of these two carbon sources 
into the lipogenic acetyl-CoA pool if it is assumed to be at iSS and that there is no 
preferential loss. Note that though D and 1-D represent relative fluxes in this case, additional 
information would be needed to determine absolute fluxes. This is in part due to multiple 
fates of acetyl-CoA in the cell beyond fatty acid synthesis and elongation, including 
oxidation, prenol and sterol lipid synthesis, and protein acetylation (Vance and Vance, 2008).
Accumulation of FASN and Elongation Products—For accumulation of elongated 
20:3n-6 and 22:4n-6 during the labeling period, the following formula was used (Equation 
12).
Ax =
Px ∗ (IE1, x + IE2, x)
cavg
(Equation 12)
Ax represents the accumulation of elongated fatty acid x during the labeling period. Px 
represents the total amount of fatty acid x in the sample. IE1,x and IE2,x represent the FASA 
parameters IE1 and IE2 for fatty acid x. cavg represents the average cell number during the 
labeling period and is calculated assuming exponential growth between starting and final 
cell counts (ci and cf, respectively) using the following formulae (Equation 13).
cavg =
ciθ 2
t f
θ − 2
ti
θ
ln 2(t f − ti)
, where θ = t ln 2
ln
c f
ci
(Equation 13)
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Θ represents the exponential doubling time, and tf and ti represent final and initial times, 
respectively.
For saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA), because data 
exists for a large number of fatty acids in a single pathway, one can go a step further and 
calculate the contribution of each pathway step to accumulated fatty acids. Note that SFA 
and MUFA of the same length were combined in this analysis because in general, the 
relevant elongases are similar (Sassa and Kihara, 2014; Vance and Vance, 2008). For a 
particular elongation step, we first determined all fatty acid origins that require having 
passed through that elongation step to exist (Figure 5B). All of the fatty acids measured and 
used in the accumulation experiments are listed in Table S5. Note that the 20:1 isotopologue 
distribution was a sum of three peaks; 20:1n-9 was identified using a standard, and the other 
two species were presumed to be 20:1n-11 and 20:1n-7 based on relative retention time and 
mass spectra. In this analysis, these fatty acids were binned as the location of the double 
bond does not affect our determinations of fatty acid source (synthesized, imported-
elongated, and imported).
Multiplying the selected parameter values by the final amount of each fatty acid divided by 
the average cell number on the plate during labeling resulted in the contributions that each 
fatty acid made to the total accumulation of elongation products through a particular 
elongation step over the labeling period (Figure 5C). Summing these individual 
contributions gave the total accumulation of elongation products for a particular elongation 
step (nmol/1e6 cells) during the labeling period (Figure 5D). This process was the same for 
synthesis, except that only S for all fatty acid was used.
QUANTIFICATION AND STATISTICAL ANALYSIS
General Statistics—General statistical details of experiments can be found in figure 
legends (definition and value of n, definition of center and dispersion measures). Unless 
otherwise stated, statistical tests were performed using a two-tailed heteroscedastic Student’s 
t test. ns (not significant) - p ≥ 0.05; * - 0.01 ≤ p < 0.05; ** - 0.001 ≤ p < 0.01; *** - p < 
0.001.
Log-Likelihood Ratio Test—The log-likelihood ratio test (LLRT) was used to compare 
the goodness of fit between FASA and ISA, as ISA can be considered to be a special case of 
FASA. p values were determined using the test statistic T and the right-tailed chi-square 
distribution with degrees of freedom f as defined below (Equation 14).
T = 2[LogL(FASA) − LogL(ISA)] = 2
SSEISA
2σ2
−
SSEFASA
2σ2
, f = mFASA − mISA (Equation 
14)
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SSEn represents the sum of squared errors for the best fit using model n. σ represents the 
standard deviation of the measurement error of the individual isotopologues in a normalized 
isotopologue distribution (a measurement of instrument noise). mn represents the number of 
parameters in model n.
In our analysis using LLRTs, we have assumed a uniform error structure (N(0,σ)) across 
isotopologues and estimated σ as < 0.4% from 20 injections of the same FAMEs standard 
(using the 7890A-5975C GC-MS). This simplified method is not a perfect representation of 
the true error structure, as rare isotopologues have smaller variances than common 
isotopologues. However, the imperfections this brings into p value calculations for the LLRT 
should be minimal. As the ISA model generally performs better in fitting common 
isotopologues, and fails at fitting rare species fit well by the FASA model, the error structure 
we assume under-penalizes ISA’s poor fitting of rare species. Therefore, using a more 
complex, but more accurate, error structure would likely lead to more significant results than 
are reported in this work.
Confidence Interval Calculation—Confidence intervals for parameter fits we estimated 
using the following equation (Equation 15):
σp = diag [J
TWJ]−1 (Equation 15)
Where σp is a vector of the estimated SDs of the fitted parameters, J is the Jacobian of the 
optimization function at the final iteration, and W is a weighting matrix, where W ii = 1 ∕ σi
2
, 
the inverse of the variance of ith measured isotopologue, yi. In the LLRT, a constant σi was 
used because as true error structure cannot be known, and using constant σi provides a more 
conservative estimate of significance (see above). However, using a constant σi for 
confidence interval calculation would lead to highly inaccurate results. Therefore, we were 
forced to modify our estimated error structure. Data from 20 repeated injections of a FAMEs 
standard mix showed that there was a roughly linear relationship between σi and AUCi for 
each yi, which therefore lead us to estimate the relative σi (RSD) of 1.67% for all yi. We 
calculated confidence intervals assuming several values for relative σi (RSD) including 2%, 
5%, and 10% to control for possible errors in RSD estimation.
DATA AND SOFTWARE AVAILABILITY
Availability of FASA Code—Source code for FASA is available at https://github.com/
BensingerLab/FASA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Fatty Acid Source Analysis (FASA) quantifies fatty acid synthesis, 
elongation, and import
• FASA improves previous models by including multiple imported-elongated 
fatty acids
• Elongation can be a major contributor to cellular fatty acid content
• Different stimuli reprogram macrophage fatty acid elongation in distinct ways
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Figure 1. ISA Yields Suboptimal Fits for Fatty Acids Containing 20–24 Carbons
H1299 shCON cells were cultured in medium containing 2% FBS, 100% U-13C6-glucose, 
and 100% U-13C5-glutamine. After 48 hr of labeling, cells were collected, and isotopologue 
distributions were determined for fatty acids.
(A–C) Representative empirical (black) and ISA-derived (red) isotopologue distributions for 
(A) 16:0, (B) 20:0, and (C) 24:0. The red bracket indicates overestimation of empirical data 
by ISA modeling, whereas the blue brackets indicate underestimation.
(D) ISA sum of squared error (SSE) for the indicated fatty acids normalized to 14:0 ISA.
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The isotopologue distributions are representative singlets of biological quadruplicates and 
are corrected for natural abundance of C, H, and O isotopes. SSEs are the average ± SD of 
biological quadruplicates. See also Figures S1–S5.
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Figure 2. FASA Significantly Improves Fits for Fatty Acids Containing 20–24 Carbons
H1299 shCON cells were cultured in medium containing 2% FBS, 100% U-13C6-glucose, 
and 100% U-13C5-glutamine. After 48 hr of labeling, cells were collected, and isotopologue 
distributions were determined for fatty acids.
(A) Schematic of possible contributions to the indicated saturated fatty acids used by FASA. 
All parameters marked in gray are considered elongated (see STAR Methods for additional 
details). S, synthesized; I, imported; IEn, imported and elongated n times.
(B) Representative empirical (black), ISA-derived (red), and FASA-derived (blue) 
isotopologue distributions for 16:0.
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(C) Model-derived contribution parameters for the 16:0 pool.
(D) Representative empirical, ISA-derived, and FASA-derived isotopologue distributions for 
24:0. The red bracket indicates overestimation of empirical data by ISA modeling, whereas 
the blue bracket indicates underestimation.
(E) Model-derived contribution parameters for the 24:0 pool.
(F) SSE for ISA and FASA, normalized to 14:0 ISA.
(G) Model-derived D (fractional contribution of 13C-labeled metabolites to the lipogenic 
acetyl-CoA) for the indicated fatty acids using ISA or FASA.
The isotopologue distributions shown are representative singlets of biological quadruplicates 
and are corrected for natural abundance of C, H, and O isotopes. Data shown for pool 
contribution parameters, SSEs, and D are the average ± SD of biological quadruplicates. See 
also Figures S1–S6 and S8–S11 and Table S2.
Argus et al. Page 34
Cell Rep. Author manuscript; available in PMC 2019 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. FASA Provides Good Fits for Polyunsaturated Fatty Acids
H1299 shCON cells were cultured in medium containing 2% FBS, 100% U-13C6-glucose, 
and 100% U-13C5-glutamine. After 48 hr of labeling, cells were collected, and isotopologue 
distributions were determined for fatty acids. When applying FASA to polyunsaturated fatty 
acids (PUFAs), values for D0, D1, and D2 were fixed using results from 16:0 to facilitate 
modeling.
(A) Schematic of possible contributions to the indicated n-6 PUFAs used by FASA. All 
parameters marked in gray are considered elongated.
(B) Representative empirical isotopologue distribution and FASA modeling for 22:4n-6.
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(C) FASA-derived contribution parameters for the 22:4n-6 pool.
(D) Representative empirical isotopologue distribution and FASA modeling for 20:3n-6.
(E) FASA-derived contribution parameters for the 20:3n-6 pool.
The isotopologue distributions shown are representative singlets of biological quadruplicates 
and are corrected for natural abundance of C, H, and O isotopes. Data shown for pool 
contribution parameters are the average ± SD of biological quadruplicates. See also Figure 
S7.
Argus et al. Page 36
Cell Rep. Author manuscript; available in PMC 2019 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Application of FASA to Cells at iSS and mSS Reveals a Significant Role for Elongation
H1299 cells were cultured in a sub-confluent state for 5 days in medium containing 5% FBS 
and 100% U-13C6-glucose to achieve iSS and mSS. On day 5, cells were collected, and 
isotopologue distributions were determined for fatty acids.
(A) FASA-derived D parameter values from the indicated SFAs and MUFAs.
(B) FASA-derived contribution parameters for selected SFA pools.
(C) Diagram for determining elongation and import contribution possibilities to the 20:0 
pool.
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(D) Elongation contribution for the indicated SFAs, MUFAs, and PUFAs. When applying 
FASA to PUFAs (but not SFAs or MUFAs), values for D0, D1, and D2 were fixed using 
results from 16:0 to facilitate modeling. Data shown are the average ± SD of biological 
quadruplicates.
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Figure 5. Interpretation of FASA-Derived Parameters from Fatty Acid Pools Not at iSS and/or 
mSS
H1299 shCON cells were treated with 15 ng/mL doxycycline for 96 hr. In the final 48 hr of 
doxycycline treatment, they were also labeled in medium containing 5% FBS, 100% 
U-13C6-glucose, and 100% U-13C5-glutamine. After 48 hr of labeling, cells were counted 
on-plate, collected, and analyzed for fatty acid content. When applying FASA, D0, D1, and 
D2 values for all fatty acids were fixed using results from 16:0 to facilitate modeling.
(A) Accumulated n-6 PUFA elongation products.
(B) Schematic for which SFA and MUFA origins require 18-to-20 elongation; X = 0 or 1 
desaturations in fatty acids.
(C) Accumulated 20-, 22-, and 24-carbon SFAs and MUFAs that were subject to 18-to-20 
elongation during the 48-hr labeling period.
(D) Summation of all accumulated 18-to-20 elongation products as described in (C).
(E) Accumulated SFA and MUFA elongation products.
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(F) Accumulated FASN products.
For (B)–(D), red, green, and blue indicate contributions from 20-, 22-, and 24-carbon fatty 
acids, respectively. Values represent average ± SD of biological quadruplicates.
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Figure 6. Application of FASA to Cells with Acute Metabolic Change by Silencing of SREBP
H1299 shCON and H1299 shSCAP cells were treated with 15 ng/mL doxycycline for 96 hr. 
In the final 48 hr of doxycycline treatment, they were also labeled in medium containing 5% 
FBS, 100% U-13C6-glucose, and 100% U-13C5-glutamine. After 48 hr of labeling, cells 
were collected for gene expression analysis or counted on-plate and collected for fatty acid 
analysis. When applying FASA, D0, D1, and D2 values for all fatty acids were fixed using 
results from 16:0 to facilitate modeling.
(A) mRNA expression of SCAP and selected SREBP targets with doxycycline.
(B) Accumulated SFA and MUFA elongation products.
(C) Accumulated FASN products.
(D) Accumulated n-6 PUFA elongation products.
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Values represent average ± SD (n = 3 for RNA, n = 4 for fatty acids). ns (not significant) p ≥ 
0.05, *p < 0.05, **p < 0.01, and ***p < 0.001 (two-tailed heteroscedastic Student’s t test).
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Figure 7. Metabolic Reprogramming of Fatty Acid Elongation Programs by TLRs
BMDMs were treated with a TLR2 agonist (Pam3CSK4 [PAM3], 50 ng/mL), a TLR3 
agonist (poly(I:C) [PIC], 1,000 ng/mL), or a TLR4 agonist (LPS, 50 ng/mL) or infected with 
MHV-68 (MOI = 1) in medium containing 5% FBS, 100% U-13C6-glucose, and 100% 
U-13C5-glutamine for 48 hr. Cells were collected after 24 h of labeling for gene expression 
analysis or counted on-plate and collected after 48 hr of labeling for fatty acid analysis. 
When applying FASA, D0, D1, and D2 values for all fatty acids were fixed using results from 
16:0 to facilitate modeling.
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(A) Accumulated SFAs and MUFAs that were subject to the indicated elongation step for 
non-treated (NT) and TLR-activated macrophages.
(B) Accumulated SFAs and MUFAs that were synthesized by FASN for NT and TLR-
activated macrophages.
(C) Accumulated n-6 PUFAs that were elongated in NT and TLR-activated macrophages.
(D) mRNA expression of Fasn and Elovl1-7 for NT and TLR-activated macrophages.
(E) Accumulated FASN products for NT, PIC-treated, and MHV-68-infected macrophages.
(F) Accumulated n-6 PUFA elongation products for NT, PIC-treated, and MHV-68-infected 
macrophages.
Values represent average ± SD of biological quadruplicates. ns (not significant) p ≥ 0.05, *p 
< 0.05, **p < 0.01, and ***p < 0.001 (two-tailed heteroscedastic Student’s t test). See also 
Figure S12 and Table S3.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
MHV-68 Ting-Ting Wu (UCLA) N/A
Chemicals, Peptides, and Recombinant Proteins
DMEM Thermo Fisher Cat# 11965-118
DMEM (no glucose) Thermo Fisher Cat# 11966-025
DMEM (no glucose, no glutamine, no phenol red) Thermo Fisher Cat# A14430-01
RPMI 1640 Thermo Fisher Cat# 11875-119
RPMI 1640 (no glucose) Thermo Fisher Cat# 11879-020
Optimem I Thermo Fisher Cat# 31985
FBS Omega Scientific Cat# FB-11
FBS Atlanta Biosciences Cat# S11150
FBS VWR Cat# 89510-186
FBS HyClone Cat# 16777-014
Penicillin/streptomycin Thermo Fisher Cat# 15140122
HEPES Thermo Fisher Cat# 15630-080
Sodium pyruvate Thermo Fisher Cat# 11360070
MEM non-essential amino acids solution Thermo Fisher Cat# 11140-050
L-glutamine Thermo Fisher Cat# A2916801
Trypsin-EDTA Thermo Fisher Cat# 25200-056
FuGENE 6 Promega Cat# E2691
Blasticidin Invivogen Cat# ant-bl-1
Puromycin Gemini Cat# 400128P100MG
RBC lysis buffer Sigma-Aldrich Cat# R7757
Recombinant M-CSF generated from CMG14-12 culture 
supernatant Takeshita et al., 2000 N/A
Dharmafect 4 Thermo Fisher Cat# T-2004-03
U-13C6-D-glucose (MPT grade) Cambridge Isotopes Laboratories Cat# CLM-1396-MPT-PK
U-13C5-L-glutamine (MPT grade) Cambridge Isotopes Laboratories Cat# CLM-1822-H-MPT-PK
Doxycycline hyclate Sigma-Aldrich Cat# D9891-10G
Pam3CSK4 Invivogen Cat# tlrl-pms
Poly(I:C) Invivogen Cat# tlrl-pic
Lipopolysaccharaide (LPS) Invivogen Cat# tlrl-smlps
Trypan blue stain solution Thermo Fisher Cat# ICN1691049
Acridine Orange Thermo Fisher Cat# A1301
Propidium Iodide VWR Cat# 80057
Calcein AM Santa Cruz Biotechnologies Cat# sc-203865
TRIzol Thermo Fisher Cat# 15596026
GLC-96 (methyl esters) Nu-Chek Prep Cat# GLC-96
18:1n-7 methyl ester Nu-Chek Prep Cat# U-48-M
19:0 methyl ester Nu-Chek Prep Cat# N-19-M
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REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems Cat# 4368813
KAPA SYBR FAST qPCR Master Mix (2X) optimized for 
LightCycler 480 KAPA Biosystems Cat# KK4601
Gateway LR Clonase II Thermo Fisher Cat# 11791-020
Experimental Models: Cell Lines
NCI-H1299 ATCC Cat# CRL-5803; RRID:CVCL_0060
H1299 shCON This paper N/A
H1299 shSCAP This paper N/A
Murine bone marrow-derived macrophages Generated at UCLA N/A
Primary Human Fibroblasts Coriell Institute Cat # ND38530; RRID:CVCL_EZ28
293FT Harvey Herschman (UCLA) N/A
Experimental Models: Organisms/Strains
Mouse: C57BL/6J The Jackson Laboratory RRID: IMSR_JAX:000664
Oligonucleotides
siControl GE Dharmacon Cat# D-001810-02-05
siELOVL1 GE Dharmacon Cat# L-009355-01-0005
See Table S4 for shRNA sequences This paper N/A
See Table S4 for qPCR primer sequences This paper N/A
Recombinant DNA
pENTR/H1/TO Thermo Fisher Cat# K4920-00
pLentipuro/BLOCK-iT-DEST Abel et al., 2013 N/A
pLP1 Thermo Fisher Cat# K4975-00
pLP2 Thermo Fisher Cat# K4975-00
pLP/VSV-G Thermo Fisher Cat# K4975-00
pLenti0.3/EF/GW/IVS-Kozak-TetR-P2A-Bsd Abel et al., 2013 N/A
Software and Algorithms
Natural Isotope Abundance Correction Algorithm This paper N/A
convISA Tredwell and Keun, 2015 N/A
Fatty Acid Source Analysis (FASA) This paper https://github.com/BensingerLab/FASA
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